 |
Prospector
Profile
07.1495
|
| |
| Urigen Pharmaceuticals, Inc. |
NAICS |
541710 |
| 875 Mahler Road, Suite 235
Burlingame, CA 94010 |
Description |
Biotechnology |
| (650) 259-0239 |
Employees |
4 |
| http://www.urigen.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-3.7330 |
| |
Assets |
(mil) |
1.1090 |
| |
Liability |
(mil) |
0.6740 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Burr Pilger & Mayer LLP raised substantial doubt about the ability of Urigen Pharmaceuticals, Inc. to continue as a going concern after auditing its financial statements. The auditor points out that the Company has incurred operating losses since inception, including a net loss of $3.7 million for the fiscal year ended June 30, 2007, negative cash flows from operations of $4.5 million for the fiscal year ended June 30, 2007, and accumulated deficit was $243.7 million at June 30, 2007. The Company requires additional financial resources to fund the completion of its development plan.
|
| |
|
Intellectual Property:
The Company has multiple intellectual property filings around its products. In general, the Company plans to file for broad patent protection in all markets where it intends to commercialize its products. Typically, the Company will file patents first in the United States or Canada and expand the applications internationally under the Patent Cooperation Treaty. Currently, the Company owns or licensed two issued patents and three patent applications. Based on these filings, the Company anticipates that lead product URG101, may be protected until at least 2025 and URG300 urethral suppository platform will be protected until at least 2018 and potentially beyond 2025. [SEC Filing 10-K 10-05-07]
|
| |
|
Description:
The Company develops and commercializes therapeutic products for urological disorders.
|
| |
|
Officers:
Benjamin F. McGraw, III (Chair); William J. Garner (Pres., CEO & Dir.); Martin E. Shmagin (CFO & Dir.); Terry M. Nida (COO); George M. Lasezkay (Dir.); Tracy Taylor (Dir.); C. Lowell Parsons (Dir.)
|
| |
|
Auditor:
Burr Pilger & Mayer LLP
|
| |
|
Securities:
Common Stock-Symbol URGP.OB; OTC BB;
68,289,535 common shares outstanding as of October 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
